Annals of Tropical Medicine and Public Health
Home About us Ahead Of Print Instructions Submission Subscribe Advertise Contact e-Alerts Editorial Board Login 
Users Online:845
  Print this page  Email this page Small font sizeDefault font sizeIncrease font size
Year : 2011  |  Volume : 4  |  Issue : 1  |  Page : 54-56

Cervical cancer vaccine: Exploring new opportunities and challenges for developing countries

1 Department of Community Medicine, Maulana Azad Medical College, New Delhi, India
2 Indian Institute of Cytology and Preventive Oncology (ICMR), Sector-39, Noida, India

Correspondence Address:
Ananya Ray Laskar
01, Abhyant Apartments, Vasundhra Enclave, Near Noida, Delhi-110096
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1755-6783.80540

Rights and Permissions

Cervical cancer is the second most common cancer in women worldwide, and the burden of the disease is disproportionately high in the developing world (>80%). With the advent of two new vaccines, "Gardasil" developed by Merck & Co. New Jersey, USA and "Cervarix" developed by GlaxoSmithKline (GSK) in Philadelphia, USA, the future holds newer promises for prevention and control of the disease. However, various regulatory and policy changes also may be required to be undertaken and the various new challenges need to be addressed.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded14    
    Comments [Add]    

Recommend this journal